NewAmsterdam Pharma (NAMS) Total Liabilities (2021 - 2026)
NewAmsterdam Pharma (NAMS) posted Total Liabilities of $67.4 million for Q1 2026, down 21.47% sequentially from $85.9 million in Q4 2025, and up 64.24% YoY from $41.0 million in Q1 2025.
NewAmsterdam Pharma (NAMS) Total Liabilities (2021 - 2026) Analysis & Trends
NewAmsterdam Pharma has reported Total Liabilities for 6 years, with the latest figure at $67.4 million in Q1 2026.
- Quarterly Total Liabilities rose 64.24% year-over-year to $67.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $67.4 million (up 64.24% YoY) and the FY2025 annual result came in at $85.9 million, down 19.85% from the prior year.
- Total Liabilities declined to $67.4 million in Q1 2026 per NAMS's latest filing, from $85.9 million in the prior quarter.
- Over five years, Total Liabilities peaked at $542.3 million in Q4 2022 and troughed at $36.6 million in Q2 2025.
- A 5-year average of $142.2 million and a median of $63.9 million in 2024 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2022 and 2023: Total Liabilities jumped 693.03% in 2022, then sank 89.18% in 2023.
- Over 5 years, Total Liabilities stood at $542.3 million in 2022, then tumbled by 89.18% to $58.7 million in 2023, then surged by 82.47% to $107.1 million in 2024, then retreated by 19.85% to $85.9 million in 2025, then slipped by 21.47% to $67.4 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $67.4 million, $85.9 million, and $58.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | NewAmsterdam Pharma | 3.17 Bn | 3.17 Bn | - | 73.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 73.03 Mn |
| Mar 31, 2026 | 67.42 Mn |
| Dec 31, 2025 | 85.85 Mn |
| Sep 30, 2025 | 58.36 Mn |
| Jun 30, 2025 | 36.62 Mn |
| Mar 31, 2025 | 41.05 Mn |
| Dec 31, 2024 | 107.12 Mn |
| Sep 30, 2024 | 60.33 Mn |
| Jun 30, 2024 | 59.25 Mn |
| Mar 31, 2024 | 76.66 Mn |
| Dec 31, 2023 | 58.70 Mn |
| Jun 30, 2023 | 512.99 Mn |
| Dec 31, 2022 | 542.35 Mn |
| Dec 31, 2021 | 68.39 Mn |